Literature Search:

Excerpta Medica

A search of Excerpta Medica from 1974 to the present turns up these articles in addition to those found by Medline:

1. Human prostatic steroid 5alpha-reductase isoforms - A comparative study of selective inhibitors

Iehle C.; Delos S.; Guirou O.; Tate R.; Raynaud J.-P.; Martin P.-M., Lab de Cancerologie Experimentale, Faculte de Medecine, Secteur Nord, Bd Pierre Dramard, 13916 Marseille Cedex 20 France

Journal of Steroid Biochemistry and Molecular Biology (United Kingdom), 1995, 54/5-6 (273-279)

LANGUAGES: English

The present study describes the independent expression of the type 1 and 2 isoforms of human 5alpha-reductase in the baculovirus-directed insect cell expression system and the selectivity of their inhibition. The catalytic properties and kinetic parameters of the recombinant isozymes were consistent with published data. The type 1 isoform displayed a neutral (range 6-8) pH optimum and the type 2 isoform an acidic (5-6) pH optimum. The type 2 isoform had higher affinity for testosterone than did the type 1 isoform (K(m) = 0.5 and 2.9 microM, respectively). Finasteride and turosteride were selective inhibitors of the type 2 isoform (K(i) (type 2) = 7.3 and 21.7 nM compared to K(i) (type 1) = 108 and 330 nM, respectively). 4-MA and the lipido-sterol extract of Serenoa repens (LSESr) markedly inhibited both isozymes (K(i) (type 1) = 8.4 nM and 7.2 microg/ml, respectively; K(i) (type 2) = 7.4 nM and 4.9 microg/ml, respectively). The three azasteroids were competitive inhibitors vs substrate, whereas LSESr displayed non-competitive inhibition of the type 1 isozyme and uncompetitive inhibition of the type 2 isozyme. These observations suggest that the lipid component of LSESr might be responsible for its inhibitory effect by modulating the membrane environment of 5alpha-reductase. Partially purified recombinant 5alpha-reductase type 1 activity was preserved by the presence of lipids indicating that lipids can exert either stimulatory or inhibitory effects on human 5alpha-reductase.

2. The lipidosterolic extract from Serenoa repens interferes with prolactin receptor signal

Vacher P.; Prevarskaya N.; Skryma R.; Audy M.C.; Vacher A.M.; Odessa M.F.; Dufy B., Laboratoire Neurophysiologie, CNRS URA 1200, Universite de Bordeaux II, 146 Rue Leo-Saignat, F-33076 Bordeaux Cedex France

Journal of Biomedical Science (Switzerland) , 1995, 2/4 (357-365)

LANGUAGES: English

The lipidosterolic extract from the saw palmetto Serenoa repens (LSESr) is commonly used for medical treatment of benign prostatic hypertrophia due to its ability to inhibit 5alpha-reductase which permits the conversion of testosterone to dihydrotestosterone, the active androgen on prostate cell proliferation. However, the complete action mechanism of LSESr is still unknown. Several lines of evidence suggest that, in addition to inhibition of 5alpha-reductase, it may interfere with the action of prolactin (PRL). We therefore investigated a possible interference of this plant extract with another hormone that controls prostate gland growth, PRL. As the action mechanism of PRL is now fully documented in Chinese hamster ovary cells expressing the PRL receptor, we have conducted our experiments on these cells. In this study, using electrophysiological (whole-cell recording and single-channel recording), microspectrofluorimetric and biochemical techniques, we show that LSESr (1-30 microg/ml) reduced the basal activity of a K+ channel and of protein kinase C (PKC) in CHO cells. In addition, pretreatment of the cells with 1-10 microg/ml LSESr for 6-36 h abolished the effects of PRL on (Ca2+)(i), K+ conductance and PKC. LSESr may block PRL-induced prostate growth by inhibiting several steps of PRL receptor signal transduction. LSESr may also be useful for diseases implicating PRL.

3. Serenoa repens capsules: A bioequivalence study

De Bernardi Di Valserra M.; Tripodi A.S.; Contos S.; Germogli R., Institute of Pharmacology II, Toxicology Chair II, University of Pavia, Pavia, Italy

ACTA TOXICOL. THER. (Italy) , 1994, 15/1 (21-39)

LANGUAGES: English SUMMARY LANGUAGES: Italian; English

A bioequivalence study of a new Serenoa repens 320 mg capsule formulation was carried out in 12 healthy male subjects in order to evaluate plasma concentration/time curve and to perform standard bioequivalence analysis in comparison to a reference 160 mg preparation. This open, randomized study had a single-dose (320 mg), crossover design and consisted of two trial periods separated by a one-week wash-out period. A sensitive, validated HPLC method was used to analyze plasma concentrations of Serenoa repens 2nd component. Bioequivalence was accepted if the 90% confidence interval (parametric or non-parametric) for the ratios (or differences) of the median values of the target variables (AUC, Cmax and Tmax) was completely within the bioequivalence range (from 80% to 125%). The plasma concentration-time profile of both preparations was nearly identical. The ratio of AUC (extent of absorption) was 1.026 (90% confidence interval 0.992-1.062), the ratio of Cmax (rate of absorption) was 0.982 (90%-confidence interval 0.930-1.038), the difference of Tmax (rate of absorption) was 0 hours (90%-confidence interval from 0 to 0.25 hours). In conclusion, one capsule of the test and two capsules of the reference product investigated can be regarded as bioequivalent with regard to the rate and extent of Serenoa repens 2nd component absorption. The tolerance of the drugs was excellent: no adverse effects were reported and laboratory analyses do not show clinical or statistical variations.

4. [Rectal bioavailability and pharmacokinetics in healthy volunteers of serenoa repens new formulation] BIODISPONIBILITA E FARMACOCINETICA PER VIA RETTALE NEL VOLONTARIO SANO DI UNA NUOVA FORMULAZIONE DI SERENOA REPENS

De Bernardi Di Valserra M.; Tripodi A.S., Cattedra di Tossicologia II, Istituto di Farmacologia II, Universita di Pavia, Pavia, Italy

ARCH. MED. INTERNA (Italy) , 1994, 46/2 (77-86)

LANGUAGES: Italian SUMMARY LANGUAGES: Italian; English

The bioavailability and pharmacokinetic profile of a new developed 640 mg rectal Serenoa repens extract preparation were determined in 12 healthy male volunteers. Drug was administered at dose of 640 mg, blood samples were collected at 0,5-1-1,5-2-3-4-6-8 and 10 hours after, and plasma concentrations of Serenoa repens 2nd component were quantified by a HPLC-method. Mean maximum concentration of 2nd component in plasma of nearly 2.60 microg/ml about 3 hours after drug intake with mean value for the area under the curve AUC(0-inf) of 10microgh/ml were observed. The bioavailability and pharmacokinetic profile of a 640 mg rectal Serenoa repens extract preparation were quite similar to those observed after oral Serenoa repens administration, only T(max) occurred about 1 h later and Serenoa repens 2nd component plasma concentration 8 hours after drug administration was still quantified. The drug tolerability was good and no adverse effect were observed.

5. [Clinical controlled trial on therapeutical bioequivalence and tolerability of Serenoa repens oral capsules 160 mg or rectal capsules 640 mg] SPERIMENTAZIONE CLINICA CONTROLLATA SULLA BIOEQUIVALENZA TERAPEUTICA E SULLA TOLLERABILITA DEI PRODOTTI A BASE DI SERENOA REPENS IN CAPSULE DA 160 MG O CAPSULE RETTALI DA 640 MG

Roveda S.; Colombo P., Catt di Gastroenterologia Chirurgica, Ist di Clinica Chirurgica Generale, Universita di Pavia, Pavia, Italy

ARCH. MED. INTERNA (Italy) , 1994, 46/2 (61-75)

LANGUAGES: Italian SUMMARY LANGUAGES: Italian; English

An open, randomized, controlled study was performed in 60 benign prostatic hypertrophy patients. The patients were randomized into two groups, the 1st (30 cases) receiving Serenoa repens oral capsules (160 mg four times a day) for 30 days and 2nd (30 cases) receiving Serenoa repens rectal capsules (640 mg once a day) for 30 days. Clinical efficacy was evaluated by means of diminution of scores assigned to dysuria, pollakiuria, prostate dimension and micturation residue. No significant differences were found between the two groups and therefore the postulated therapeutic bioequivalence between the two therapies was demonstrated.

6. Prostaserene (R). Treatment for BPH

Bruhwyler J., Therabel Research Biostatistics, Chaussee d'Alsemberg 1001, B-1180 Bruxelles, Belgium

DRUGS FUTURE (Spain) , 1994, 19/5 (452-453)

LANGUAGES: English SUMMARY LANGUAGES: English

Serenoa repens extract is a potential therapeutic alternative for the treatment of mild to moderate symptoms of benign prostatic hyperplasia, and appears to be safe and effective in the treatment of micturition problems associated with BPH.

7. The extract of serenoa repens in the treatment of benign prostatic hyperplasia: A multicenter open study

Braeckman J., Department of Urology, AZ, VUB, Laarbeeklaam 101, 1090 Brussels, Belgium

CURR. THER. RES. CLIN. EXP. (USA) , 1994, 55/7 (776-785)

LANGUAGES: English

Because prostatic surgery is not the treatment of choice for most patients with benign prostatic hyperplasia (BPH), the therapeutic effect of a 160-mg, twice-daily, oral dose of Serenoa repens extract was studied during a 3-month open trial in 505 patients with mild-tomoderate symptoms of BPH. The efficacy of the regimen was evaluated in 305 of these patients. Traditional parameters for quantifying prostatism, such as the International Prostate Symptom Score, the quality of life score, urinary flow rates, residual urinary volume, and prostate size, were found to be significantly improved after only 45 days of treatment. After 90 days of treatment, a majority of patients (88%) and treating physicians (88%) considered the therapy effective. In addition, the serum prostate-specific antigen concentration was not modified by the drug, thus limiting the risk of masking any possible development of prostate cancer during treatment. The incidence of side effects (5%) was low and compares favorably with that reported for existing medical therapies used in BPH patients. The extract of Serenoa repens appears to be an effective and well-tolerated pharmacologic agent in treating the mictional problems accompanying BPH.

8. [The antiestrogenic activity of sabal in the prostatic tissue of patients with benign prostate hypertrophy] ATTIVITA ANTIESTROGENICA DELLA SERENOA REPENS B IN TESSUTO PROSTATICO DI PAZIENTI CON IPERTROFIA PROSTATICA BENIGNA

Caponera M.; D'Eramo G.; Flammia G.P.; Sciarra A.; Frascaro F.; Macri D.; Di Silverio F., Dipartimento di Urology 'U. Bracci', Policlinico Umberto I, 00161 Roma Italy

ACTA UROL. ITAL. (Italy) , 1992, 6/SUPPL. 4 (271-272)

LANGUAGES: Italian SUMMARY LANGUAGES: English

9. [Phytotherapy of benign prostate hyperplasia with Serenoa repens extract (permixon (R))] PHYTOTHERAPIE DER BENIGNEN PROSTATAHYPERPLASIE (BPH) MIT EXTRACTUM SERENOA REPENS (PEMIXON (R))

Dathe G.; Schmid H., Klinik fur Urologie, St. Markus-Krankenhaus, Akademisches Lehrkrankenhaus, Johann-Wolfgang-Goethe-Universitat, Wilh.-Epstein-Strasse 2, W-6000 Frankfurt 50, Germany

UROLOGE AUSG. B (Germany) , 1991, 31/5 (220-223)

LANGUAGES: German SUMMARY LANGUAGES: German

10. [Drug therapy of benign prostate hyperplasia with Serenoa repens extract] MEDIKAMENTOSE THERAPIE DER BENIGNEN PROSTATAHYPERPLASIE MIT EINEM EXTRAKT DER SAGEPALME

Mattei F.M.; Capone M.; Acconcia A., Ospedale Rinuiti Santa Maria, Siena, Italy

TW UROL. NEPHROL. (Germany, Federal Republic of) , 1990, 2/5 (346-350)

LANGUAGES: German SUMMARY LANGUAGES: English

11. [Portrait of a medicinal plant Serenoa repens. Saw palmetto] SERENOA REPENS - DIE SAGEZAHNPALME

Harnischfeger G.; Stolze Hispanic., Schaper und Brummer GmbH, 3320 Salzgitter 61, Federal Republic of Germany

Z. PHYTOTHER. (Germany, Federal Republic of) , 1989, 10/2 (71-76)

LANGUAGES: German SUMMARY LANGUAGES: English

12. Liposterolic extract of Serenoa Repens in management of benign prostatic hypertrophy

Mattei F.M.; Capone M.; Acconcia A., Spedali Riuniti S. Maria della Scala di Siena, Divisione di Urologia, Siena, Italy

UROLOGIA (Italy) , 1988, 55/5 (547-552)

LANGUAGES: Italian

13. Treatment of prostate adenoma with Serenoa Repens extract

Martorana G; Giberti C.; Pizzorno R.; Natta G.D.; Brancadoro M.T.; Barreca T.; Rolandi E.; Isotta A.; Neumaier C.E., Patologia Medica R dell'Universita di Genova, Genova, Italy

UROLOGIA (Italy) , 1986, 53/3 (366-369) LANGUAGES: Italian SUMMARY LANGUAGES: English

14. Serenoa Repens in management of chronic prostatitis and non-bacterial prostatitis

Proietti G., Ospedale S. Giovanni di Roma, Divisione di Urologia, Roma, Italy

UROLOGIA (Italy) , 1986, 53/3 (361-365)

LANGUAGES: Italian SUMMARY LANGUAGES: English

15. [Urodynamic evaluation of management of prostatic adenoma with Serenoa Repens extract] VALUTAZIONE URODINAMICA DEL TRATTAMENTO NEI PAZIENTI AFFETTI DA ADENOMA PROSTATICO CON ESTRATTO DI SERENOA REPENS

Pescatore D.; Calvi P.; Michelotti P., Italy

UROLOGIA (Italy) , 1986, 53/6 (894-897) CODEN: UROTA ISSN: 0391-5603

LANGUAGES: Italian SUMMARY LANGUAGES: English

15. Behavior of seminal parameters after management with Serenoa Repens

D'Ottavio G.; Lagana A.; Zappavigna D., U.L.S.S. RM18, Ospedale San Carlo di Nancy di Roma, Divisione di Chirurgia Generale, Unita di Urologia-Andrologia, Roma, Italy

UROLOGIA (Italy) , 1987, 54/5 ( 616-621)

LANGUAGES: Italian SUMMARY LANGUAGES: English

16. Treatment of benign prostatic hypertrophy with Serenoa Repens

Vespasiani G.; Cesaroni M.; Parziani S.; Rosi P.; Valentini P.; Porena M., Clinica Urologica dell'Universita di Perugia, Perugia, Italy

UROLOGIA (Italy) , 1987, 54/2 (145-149)

LANGUAGES: Italian SUMMARY LANGUAGES: English

17. Mepartricin vs. Serenoa repens: Double-blind study in 20 cases of benign prostate hypertrophy

Comar O.B.; Di Rienzo A., Presidio Ospedaliero Multizonal, Divisone di Urologia, U.S.L. N. 4, Avellino, Italy

RIV. ITAL. BIOL. MED. (Italy) , 1986, 6/2 (122-125)

LANGUAGES: Italian SUMMARY LANGUAGES: English; French

18. Serenoa repens in treatment of benign prostate hypertrophy

Mancuso G.; Guillot F.; Migaleddu V.; Satta U., Istituto di Radiologia dell'Universita, Sassari, Italy

UROLOGIA (Italy) , 1986, 53/5 (709-714)

LANGUAGES: Italian

19. Serenoa repens vs. gestonorone caproate in treatment of benign prostate hypertrophy

Pannunzio E.; D'Ascenzo R.; Giardinetti F.; Civili P.; Persichelli E., Divisione di Urologia, Ospedale Fatebenefratelli S. Giovanni Calibita, Roma, Italy

UROLOGIA (Italy) , 1986, 53/5 (696-705)

LANGUAGES: Italian

20. Preliminary results with extract of Serenoa repens in treatment of prostatitis

Lunghi F.; Bartoletti R.; Serni S.; Dami A., Clinica Urologica dell'Universita di Firenze, Firenze, Italy

UROLOGIA (Italy) , 1986, 53/5 (663-667)

LANGUAGES: Italian

21. [Our experience with hexanic extract of Serenoa repens in the treatment of benign prostatic hypertrophy] NUESTRA EXPERIENCIA CON EXTRACTO HEXANICO DE SERENOA REPENS EN EL TRATAMIENTO DE LA HIPERTROFIA BENIGNA DE PROSTATA

Carrerras J.O., Servicio de Urologia, Hospital 'Virgen de la Salud, 45004 Toledo, Spain

ARCH. ESP. UROL. (Spain) , 1987, 40/5 ( 310-313)

LANGUAGES: Spanish SUMMARY LANGUAGES: English

22. [Serenoa Repens in medical therapy of B.P.H.] TRATTAMENTO MEDICO DELL'IPERTROFIA PROSTATICA. ESPERIENZA CON L'IMPIEGO TERAPEUTICO DI SERENOA REPENS

Paoletti P.P.; Francalanci R.; Tenti S.; et al., Divisione di Urologia, Ospedale Civile, Arezzo, Italy

UROLOGIA (ITALY) , 1986, 53/2 (182-187+LV)

LANGUAGES: ITALIAN SUMMARY LANGUAGES: ENGLISH

23. [Clinical trials of a liposterolic extract of Serenoa repens] PERMIXON: LES PREUVES CLINIQUES FRANCE

GAZ. MED. (FRANCE) , 1986, 93/1 SUPPL. (34-36)

LANGUAGES: FRENCH

24. [Medical treatment of benign prostate hypertrophy with a liposterolic extract of Serenoa repens] TRAITEMENT MEDICAL DE L'HYPERTROPHIE PROSTATIQUE BENIGNE PAR PERMIXON FRANCE

GAZ. MED. (FRANCE) , 1986, 93/1 SUPPL. (30-31)

LANGUAGES: FRENCH

25. [Treatment of obstruction in prostatic adenoma using an extract of serenoa repens. Double-blind clinical test v. placebo] TRATTAMENTO DELLA SINTOMATOLOGIA OSTRUTTIVA DA ADENOMA PROSTATICO CON ESTRATTO DI SERENOA REPENS. STUDIO CLINICO IN DOPPIO CIECO VS. PLACEBO

Tasca A.; Barulli M.; Cavazzana A.; et al., Universita di Padova, Istituto di Urologia, Monoblocco Ospedale Civile, Padova, Italy

MINERVA UROL. NEFROL. (ITALY) , 1985, 37/1 (87-91)

LANGUAGES: ITALIAN SUMMARY LANGUAGES: ENGLISH

26. [Serenoa repens extract vs. placebo] PERMIXON VERSUS PLACEBO. RESULTATS D'UNE ETUDE MULTICENTRIQUE

Cukier; Ducassou; Le Guillou; et al., Laboratoires Fabre, P.F. Medicament, 81106 Castres Cedex, France

C R. THER. PHARMACOL. CLIN. (FRANCE) , 1985, 4/25 (15-21)

LANGUAGES: FRENCH SUMMARY LANGUAGES: ENGLISH

27. [Treatment of benign prostatic hyperplasia with Serenoa Repens extract (Permixon)] L'ESTRATTO DI SERENOA REPENS (PERMIXON(Reg.trademark)) NEL TRATTAMENTO PRECOCE DELL'IPERTROFIA PROSTATICA

Cirillo-Marucco E.; Pagliarulo A.; Tritto G.; et al., Universita degli Studi di Bari, Cattedra de Urologia, Bari, Italy

UROLOGIA (ITALY) , 1983, 50/6 (1269-1277)

LANGUAGES: ITALIAN SUMMARY LANGUAGES: ENGLISH

28.[Serenoa Repens extract and placebo in prostatic benign hyperplasia. Clinical results] CONFRONTO FRA ESTRATTO DI SERENOA REPENS E PLACEBO MEDIANTE PROVA CLINICA CONTROLLATA IN PAZIENTI CON ADENOMATOSI PROSTATICA

Boccafoschi C.; Annoscia S., Universita degli Studi di Trieste, Clinica Urologica, Trieste, Italy

UROLOGIA (ITALY) , 1983, 50/6 (1257-1268)

LANGUAGES: ITALIAN SUMMARY LANGUAGES: ENGLISH

29. [A new medical treatment of prostatic benign hyperplasia] TERAPIA MEDICA DELL'ADENOMA PROSTATICO: CONFRONTO DELLA EFFICACIA DELL'ESTRATTO DI SERENOA REPENS (PERMIXON(Reg.trademark)) VERSUS L'ESTRATTO DI PIGEUM AFRICANUM E PLACEBO. VALUTAZIONE IN DOPPIO CIECO

Mandressi A.; Tarallo U.; Maggioni A.; et al., Istituto di Urologia dell'Universita di Milano, Milano, Italy

UROLOGIA (ITALY) , 1983, 50/4 (752-757)

LANGUAGES: ITALIAN SUMMARY LANGUAGES: ENGLISH

30. [Anti-edematous action of an hexane extract from Serenoa repens Bartr. Drupes] ACTION ANTI-OEDEMATEUSE D'UN EXTRAIT HEXANIQUE DE DRUPES DE SERENOA REPENS BARTR.

Tarayre J.P.; Delhon A.; Lauressergues H.; Stenger A., Centre de Recherches Pierre Fabre, F 81106 Castres, France

ANN. PHARM. FR. (FRANCE) , 1983, 41/6 (559-570)

LANGUAGES: FRENCH SUMMARY LANGUAGES: ENGLISH

31. [Pharmacology and biochemistry of hexane extract of Serenoa repens (PA-109)] ETUDE PHARMACOLOGIQUE ET BIOCHIMIQUE DE L'EXTRAIT HEXANIQUE DE SERENOA REPENS B (PA 109)

Stenger A.; Tarayre J.P.; Carilla E.; et al., Cent. Rech. Pierre Fabre, 81106 Castres Cedex, France

GAZ. MED. FR. (FRANCE) , 1982, 89/17 (2041-2048)

LANGUAGES: FRENCH

Last modified: January 15, 2001

Go back to David Mendosa's Home Page

Go back to David Mendosa's Saw Palmetto Page